CANDIDATES FOR PTNM
For some OAB patients, pharmacology is adequate. However, as many as 7 in 10 patients give up taking medication within 6 months.1,2 Patient compliance with medications such as anticholinerginics is low due to variable efficacy and side effects, such as dry mouth and constipation.3
PTNM, delivered by the Medtronic NURO™ system, expands your treatment options for OAB patients who:
- Have overactive bladder with symptoms of urinary urgency, urinary frequency, or urge incontinence
- Are seeking an alternative to oral medications
- Prefer an office-based treatment
- Are not a candidate for sacral neuromodulation (SNM)
- Need a lower-body MRI
- Are unwilling or unable to tolerate the potential need for self-catheterization
Third line OAB treatment options include:
- PTNM – a periodic office-based procedure that requires no drugs or surgery
Most common side effects of PTNM are temporary and include mild pain or skin inflammation at or near the stimulation site.
- Sacral Neuromodulation – continuous bladder control with the implanted InterStim™ system (see indications, safety and warnings)
- Intradetrusor Onabotulinum toxin A (BOTOX®) – a periodic office-based procedure
- Haab, F. and D. Castro-Diaz (2005). Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract 59(8): 931-937.
- Yeaw, J., J. S. Benner, et al. (2009). Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15(9): 728-740.
- Gormley, E. A., D. J. Lightner, et al. (2015). Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 193(5): 1572-1580.